Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial
Authors:
- Malgorzata BanysMalgorzata Banys
- Erich-Franz SolomayerESErich-Franz Solomayer
- Gerhard GebauerGGGerhard Gebauer
- Wolfgang JanniWJWolfgang Janni
- Natalia KrawczykNKNatalia Krawczyk
- Sven BeckerSven Becker
- Jens HuoberJHJens Huober
- Bernhard KraemerBKBernhard Kraemer
- Birgit WackwitzBWBirgit Wackwitz
- Peter HirnlePHPeter Hirnle
- Diethelm WallwienerDWDiethelm Wallwiener
Open Access
- 15 October 2013
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 480
Abstract
Background: The presence of disseminated tumor cells (DTC) in bone marrow (BM) of breast cancer patients is associated with reduced clinical outcome. Bisphosphonate treatment was shown to eradicate DTC from BM in several studies. This controlled randomized open-label multi-center study aimed to investigate the influence of zoledronic acid (ZOL) on DTC and survival of breast cancer patients (Clinical Trial Registration Number: NCT00172068). Methods: Patients with primary breast cancer and DTC-positive bone marrow were randomized to treatment with ZOL plus adjuvant systemic therapy (n = 40) or adjuvant systemic therapy alone (n = 46) between 03/2002 and 12/2004. DTC were identified by immunocytochemistry using the pancytokeratin antibody A45B/B3 and by cytomorphology. The change in DTC numbers at 12 months and 24 months versus baseline, as well as patient outcomes were evaluated. Results: 86 patients could be included into survival analysis (median follow-up: 88 months, range: 8–108 mths). Patients in the control group were more likely to die during follow-up than those in the ZOL-group (11% vs. 2%, p = 0.106). 15% of patients in the control group presented with relapse whereas only 8% of ZOL group patients developed metastatic or recurrent disease during follow-up (p = 0.205). At 24 months, 16% of patients from the control group were still DTC positive, whereas all patients treated with ZOL became DTC negative (p = 0.032). Patients presenting with persistent DTC 12 months after diagnosis had significantly shorter overall survival (p = 0.011). Conclusions: Bisphosphonate therapy contributes to eradication of disseminated tumor cells. The positive influence of bisphosphonates on survival in the adjuvant setting may be due to their effects on DTC. Trial registration: ClinicalTrials.gov Identifier: NCT00172068 [Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow (MRD-1)].Keywords
This publication has 37 references indexed in Scilit:
- Breast-Cancer Adjuvant Therapy with Zoledronic AcidNew England Journal of Medicine, 2011
- The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancerBreast Cancer Research and Treatment, 2011
- Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialThe Lancet Oncology, 2010
- The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerBritish Journal of Cancer, 2010
- The metastatic niche: adapting the foreign soilNature Reviews Cancer, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patientsBreast Cancer Research and Treatment, 2007
- A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementationCancer, 2006
- A Pooled Analysis of Bone Marrow Micrometastasis in Breast CancerNew England Journal of Medicine, 2005
- The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrenceCancer, 2005